SEC Form SC 13G/A filed by ADC Therapeutics SA (Amendment)

4/10/23 9:37:12 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ADCT alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 ADC THERAPEUTICS SA COMMON STOCK Cusip #H0036K147 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #H0036K147 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 38,357 Item 6: 0 Item 7: 40,444 Item 8: 0 Item 9: 40,444 Item 11: 0.050% Item 12: HC Cusip #H0036K147 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 40,444 Item 8: 0 Item 9: 40,444 Item 11: 0.050% Item 12: IN Item 1(a). Name of Issuer: ADC THERAPEUTICS SA Item 1(b). Address of Issuer's Principal Executive Offices: BIOPOLE, ROUTE DE LA CORNICHE 3B EPALINGES, V8 1066 Switzerland Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: H0036K147 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 40,444 (b) Percent of Class: 0.050% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 40,444 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ADC THERAPEUTICS SA. No one other person's interest in the COMMON STOCK of ADC THERAPEUTICS SA is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. April 6, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on April 6, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ADC THERAPEUTICS SA at March 31, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ADCT alert in real time by email

Recent Analyst Ratings for

$ADCT

Date	Price Target	Rating	Analyst
11/8/2024	$6.00	Overweight	Stephens
5/30/2024		Overweight	Cantor Fitzgerald
3/28/2024	$11.00	Buy	Guggenheim
8/10/2023		Underweight → Neutral	JP Morgan
4/24/2023	$7.00 → $2.00	Neutral → Underperform	BofA Securities
12/6/2022	$12.00	Overweight	CapitalOne
11/9/2022	$14.00 → $7.00	Buy → Neutral	BofA Securities
9/21/2022	$5.00	Overweight	JP Morgan

More analyst ratings

SEC Form SC 13G/A filed by ADC Therapeutics SA (Amendment)

4/10/23 9:37:12 AM ET

$ADCT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ADCT alert in real time by email

Recent Analyst Ratings for

$ADCT

Date	Price Target	Rating	Analyst
11/8/2024	$6.00	Overweight	Stephens
5/30/2024		Overweight	Cantor Fitzgerald
3/28/2024	$11.00	Buy	Guggenheim
8/10/2023		Underweight → Neutral	JP Morgan
4/24/2023	$7.00 → $2.00	Neutral → Underperform	BofA Securities
12/6/2022	$12.00	Overweight	CapitalOne
11/9/2022	$14.00 → $7.00	Buy → Neutral	BofA Securities
9/21/2022	$5.00	Overweight	JP Morgan

More analyst ratings

SEC Form SC 13G/A filed by ADC Therapeutics SA (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ADCT

SEC Form SC 13G/A filed by ADC Therapeutics SA (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ADCT

$ADCT Insider Trading

Chief Executive Officer Mallik Ameet covered exercise/tax liability with 233,146 shares, decreasing direct ownership by 15% to 1,319,101 units (SEC Form 4)

Chief Medical Officer Zaki Mohamed covered exercise/tax liability with 41,068 shares, decreasing direct ownership by 9% to 421,820 units (SEC Form 4)

Chief Accounting Officer Kallebo Lisa Michelle covered exercise/tax liability with 7,140 shares, decreasing direct ownership by 9% to 70,757 units (SEC Form 4)

$ADCT SEC Filings

ADC Therapeutics SA filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

ADC Therapeutics SA filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form EFFECT filed by ADC Therapeutics SA

$ADCT FDA approvals

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

$ADCT Analyst Ratings

Stephens initiated coverage on ADC Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on ADC Therapeutics

Guggenheim initiated coverage on ADC Therapeutics with a new price target

$ADCT Insider Purchases

Large owner Redmile Group, Llc bought $609,000 worth of shares (200,000 units at $3.04) (SEC Form 4)

Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

$ADCT Press Releases

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

$ADCT Leadership Updates

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

$ADCT Financials

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

$ADCT Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

Recent Analyst Ratings for
$ADCT

Recent Analyst Ratings for
$ADCT

$ADCT
Insider Trading

$ADCT
SEC Filings

$ADCT
FDA approvals

$ADCT
Analyst Ratings

$ADCT
Insider Purchases

$ADCT
Press Releases

$ADCT
Leadership Updates

$ADCT
Financials

$ADCT
Large Ownership Changes